Registered title, quoted from ClinicalTrials.gov
QL1706 With Olaparib for Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency (HRD)
An open trial on breast cancer, registered on ClinicalTrials.gov. Led by Jiangsu Province Hospital; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07113964, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 7
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (7 points)Hide the checklist
18 years to 75 years; sex: women only
Registered eligibility fields
Pathologically documented HER2-negative locally advanced or metastatic breast cancer (IHC0, IHC 1+\& IHC 2+/ISH-) that was hormone-receptor positive (i.e., estrogen-receptor positive, progesterone-receptor positive, or both) or was triple negative.
Inclusion criterion 2
Has been treated with 2-4 previous therapy regimens for metastatic disease.
Inclusion criterion 3
Prior treatment with immune checkpoint inhibitors (ICI) (anti-CTLA-4, anti-PD-1, anti-PD-L1, combined therapy anti-PD-1/PD-L1 with anti-CTLA-4) or olaparib for advanced disease.
Exclusion criterion 2
Discontinuation of prior anti-PD-1/PD-L1/CTLA-4 therapy due to immune-related toxicity.
Exclusion criterion 5
Age 18 - 75 years; Eastern Cooperative Oncology Group (ECOG) score status 0-1.
Inclusion criterion 1
At least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors version 1.1.
Inclusion criterion 5
Has a known history of human immunodeficiency virus (HIV) infection.
Exclusion criterion 8
Female subjects of reproductive/childbearing potential must agree to use a highly effective form of contraception or avoid intercourse during and upon completion of the study and after the last dose for at least 3 months. Negative serum or urine pregnancy test within 7 days before study enrollment, and must be a non-lactating subject.
Inclusion criterion 8
Female subjects who are pregnant, lactating or plan to become pregnant during the study.
Exclusion criterion 12
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07113964, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Age 18 - 75 years; Eastern Cooperative Oncology Group (ECOG) score status 0-1.
- Pathologically documented HER2-negative locally advanced or metastatic breast cancer (IHC0, IHC 1+\& IHC 2+/ISH-) that was hormone-receptor positive (i.e., estrogen-receptor positive, progesterone-receptor positive, or both) or was triple negative.
- Has been treated with 2-4 previous therapy regimens for metastatic disease.
- HRD positive confirmed, known germline and/or systemic BRCA mutation status that is predicted to be deleterious or suspected deleterious allow preferential enrolment.
- At least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors version 1.1.
- Has protocol-defined adequate bone marrow, renal, hepatic and blood clotting functions.
- A life expectancy of at least 12 weeks.
- Female subjects of reproductive/childbearing potential must agree to use a highly effective form of contraception or avoid intercourse during and upon completion of the study and after the last dose for at least 3 months. Negative serum or urine pregnancy test within 7 days before study enrollment, and must be a non-lactating subject.
- Volunteer to participate in this study and sign the informed consent.
Exclusion Criteria:
- Has any active autoimmune disease, which may worsen when receiving immune stimulants.
- Prior treatment with immune checkpoint inhibitors (ICI) (anti-CTLA-4, anti-PD-1, anti-PD-L1, combined therapy anti-PD-1/PD-L1 with anti-CTLA-4) or olaparib for advanced disease.
- Has unresolved toxicities from previous anticancer therapy.
- Has uncontrolled or significant cardiovascular disease.
- Discontinuation of prior anti-PD-1/PD-L1/CTLA-4 therapy due to immune-related toxicity.
- Known history or evidence of interstitial lung disease or active non-infectious pneumonitis.
- Has received a live vaccine vaccination within 28 days before enrolment.
- Has a known history of human immunodeficiency virus (HIV) infection.
- Has known history of or is positive for Hepatitis B or Hepatitis C.
- Any severe or poorly controlled systemic disease such as poorly controlled hypertension, active bleeding susceptibility or active infection, as judged by the investigator.
- Has untreated or clinically active central nervous system metastases.
- Female subjects who are pregnant, lactating or plan to become pregnant during the study.
- Has any other condition that per protocol or in the opinion of the investigator is inappropriate for the study.
Quoted from ClinicalTrials.gov, NCT07113964, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07113964, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.